Corline Biomedical: Positive feedback from EMA

Redeye reiterates its positive view of Corline as EMA has decided to follow FDA’s stance of allowing a single Phase II trial in Europe as enough evidence for continued development of Renaparin. This in line with our assumptions and confirms our investment case that regulatory agencies will continue to take a lenient stance towards Renaparin..